Pancreatic cancer stem cells: New insight into a stubborn disease

Cancer Letters

Volumn 357, Issue 2, 2015, Pages 429-437

  Zhan, Han xiang ^a   Xu, Jian wei ^a   Wu, Dong ^a   Zhang, Tai ping ^b   Hu, San yuan ^a  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cancer stem cells; Chemotherapy resistance; Metastasis; MicroRNA; Pancreatic cancer

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BETA CATENIN; CABOZANTINIB; CD133 ANTIGEN; CD22 ANTIGEN; CELL MARKER; CHEMOKINE RECEPTOR CXCR4; CYCLOPAMINE; DCAMKL 1 PROTEIN; DEATH RECEPTOR 5; FORKHEAD TRANSCRIPTION FACTOR; GEMCITABINE; HERMES ANTIGEN; MICRORNA; MICRORNA 200A; MICRORNA 21; MICRORNA 34; NOTCH RECEPTOR; RAPAMYCIN; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; WNT PROTEIN;

CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL RENEWAL; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL RESEARCH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR RECURRENCE;

EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, GENETIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84920840407     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.004     Document Type: Review

References (115)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J. Clin 2014, 64(2014):9-29.
2. Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat. Rev 2014, 40:1039-1047.
3. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med 2011, 364:1817-1825.
4. Chiu J.W., Wong H., Leung R., Pang R., Cheung T.T., Fan S.T., et al. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014, 19(9):937-950.
5. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med 2013, 369:1691-1703.
6. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
7. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell stem cell 2012, 10:717-728.
8. Fessler E., Dijkgraaf F.E., De Sousa E.M.F., Medema J.P. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?. Cancer Lett 2013, 341:97-104.
9. Wang X., Zhu Y., Ma Y., Wang J., Zhang F., Xia Q., et al. The role of cancer stem cells in cancer metastasis: new perspective and progress. Cancer Epidemiol 2013, 37:60-63.
10. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
11. Castellanos J.A., Merchant N.B., Nagathihalli N.S. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco. Targets Ther 2013, 6:1261-1267.
12. Xia J., Chen C., Chen Z., Miele L., Sarkar F.H., Wang Z. Targeting pancreatic cancer stem cells for cancer therapy. Biochim. Biophys. Acta 1826, 2012:385-399.
13. Signore M., Ricci-Vitiani L., De Maria R. Targeting apoptosis pathways in cancer stem cells. Cancer Lett 2013, 332:374-382.
14. Leal J.A., Lleonart M.E. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 2013, 338:174-183.
15. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 1997, 3:730-737.
16. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
17. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
18. Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M., Gasser M., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-4333.
19. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
20. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
21. Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65:3025-3029.
22. Miki J., Furusato B., Li H., Gu Y., Takahashi H., Egawa S., et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007, 67:3153-3161.
23. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol 2013, 15:338-344.
24. Abel E.V., Simeone D.M. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013, 144:1241-1248.
25. Li C., Wu J.J., Hynes M., Dosch J., Sarkar B., Welling T.H., et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141:2218-2227. e2215.
26. Silva I.A., Bai S., McLean K., Yang K., Griffith K., Thomas D., et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011, 71:3991-4001.
27. Penchev V.R., Rasheed Z.A., Maitra A., Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin. Cancer Res 2012, 18:4277-4284.
28. O'Connor M.L., Xiang D., Shigdar S., Macdonald J., Li Y., Wang T., et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett 2014, 344:180-187.
29. Proctor E., Waghray M., Lee C.J., Heidt D.G., Yalamanchili M., Li C., et al. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS ONE 2013, 8:e55820.
30. Onishi H., Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J. Gastroenterol 2014, 20:2335-2342.
31. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
32. Maeda S., Shinchi H., Kurahara H., Mataki Y., Maemura K., Sato M., et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br. J. Cancer 2008, 98:1389-1397.
33. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6:61-73.
34. Herreros-Villanueva M., Zubia-Olascoaga A., Bujanda L. c-Met in pancreatic cancer stem cells: therapeutic implications. World J. Gastroenterol 2012, 18:5321-5323.
35. Delitto D., Vertes-George E., Hughes S.J., Behrns K.E., Trevino J.G. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J. Gastroenterol 2014, 20:8458-8470.
36. Hage C., Rausch V., Giese N., Giese T., Schonsiegel F., Labsch S., et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013, 4:e627.
37. Kim M.P., Fleming J.B., Wang H., Abbruzzese J.L., Choi W., Kopetz S., et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 2011, 6:e20636.
38. Kahlert C., Bergmann F., Beck J., Welsch T., Mogler C., Herpel E., et al. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer 2011, 11:275.
39. Duong H.Q., Hwang J.S., Kim H.J., Kang H.J., Seong Y.S., Bae I. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Int. J. Oncol 2012, 41:855-861.
40. Karamboulas C., Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta 1830, 2013:2481-2495.
41. Espinoza I., Pochampally R., Xing F., Watabe K., Miele L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco. Targets Ther 2013, 6:1249-1259.
42. Niess H., Camaj P., Renner A., Ischenko I., Zhao Y., Krebs S., et al. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Targeted Oncol 2014.
43. Abel E.V., Kim E.J., Wu J., Hynes M., Bednar F., Proctor E., et al. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS ONE 2014, 9:e91983.
44. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011, 307:26-36.
45. Cohen M.M. The hedgehog signaling network. Am. J. Med. Genet. A 2003, 123A:5-28.
46. Xie J., Bartels C.M., Barton S.W., Gu D. Targeting hedgehog signaling in cancer: research and clinical developments. Onco. Targets Ther 2013, 6:1425-1435.
47. Li S.H., Fu J., Watkins D.N., Srivastava R.K., Shankar S. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol. Cell. Biochem 2013, 373:217-227.
48. Tang S.N., Fu J., Nall D., Rodova M., Shankar S., Srivastava R.K. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int. J. Cancer 2012, 131:30-40.
49. Chen Y.J., Huang Y.C., Tsai T.H., Liao H.F. Effect of wasabi component 6-(methylsulfinyl)hexyl isothiocyanate and derivatives on human pancreatic cancer cells. Evid. Based Complement. Alternat. Med 2014, 2014:494739.
50. Han J.B., Sang F., Chang J.J., Hua Y.Q., Shi W.D., Tang L.H., et al. Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli. Onco. Targets Ther 2013, 6:1129-1138.
51. Fu J., Rodova M., Roy S.K., Sharma J., Singh K.P., Srivastava R.K., et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett 2013, 330:22-32.
52. Warrier S., Bhuvanalakshmi G., Arfuso F., Rajan G., Millward M., Dharmarajan A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther 2014, 21(9):381-388.
53. Vaz A.P., Ponnusamy M.P., Rachagani S., Dey P., Ganti A.K., Batra S.K. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. Br. J. Cancer 2014, 111:486-496.
54. Bao B., Wang Z., Ali S., Kong D., Banerjee S., Ahmad A., et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell. Biochem 2011, 112:2296-2306.
55. Quan M., Wang P., Cui J., Gao Y., Xie K. The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol. Cancer 2013, 12:159.
56. Lonardo E., Hermann P.C., Mueller M.-T., Huber S., Balic A., Miranda-Lorenzo I., et al. Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011, 9:433-446.
57. Singh S., Srivastava S.K., Bhardwaj A., Owen L.B., Singh A.P. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer 2010, 103:1671-1679.
58. Rajeshkumar N.V., Rasheed Z.A., Garcia-Garcia E., Lopez-Rios F., Fujiwara K., Matsui W.H., et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol. Cancer Ther 2010, 9:2582-2592.
59. Ceppi P., Peter M.E. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene 2014, 33:269-278.
60. Dillhoff M., Liu J., Frankel W., Croce C., Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg 2008, 12:2171-2176.
61. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther 2009, 8:1067-1074.
62. Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010, 70:4528-4538.
63. Cheng H., Shi S., Cai X., Long J., Xu J., Liu C., et al. microRNA signature for human pancreatic cancer invasion and metastasis. Exp. Ther. Med 2012, 4:181-187.
64. Agostini M., Knight R.A. miR-34: from bench to bedside. Oncotarget 2014, 5:872-881.
65. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009, 4:e6816.
66. Lu Y., Lu J., Li X., Zhu H., Fan X., Zhu S., et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer 2014, 14:85.
67. Hasegawa S., Eguchi H., Nagano H., Konno M., Tomimaru Y., Wada H., et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br. J. Cancer 2014.
68. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol 2009, 11:1487-1495.
69. May R., Sureban S.M., Lightfoot S.A., Hoskins A.B., Brackett D.J., Postier R.G., et al. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am. J. Physiol. Gastrointest. Liver Physiol 2010, 299:G303-G310.
70. Sureban S.M., May R., Lightfoot S.A., Hoskins A.B., Lerner M., Brackett D.J., et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011, 71:2328-2338.
71. Sureban S.M., May R., Qu D., Weygant N., Chandrakesan P., Ali N., et al. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS ONE 2013, 8:e73940.
72. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
73. Puisieux A., Brabletz T., Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol 2014, 16:488-494.
74. Li Y., Kong D., Ahmad A., Bao B., Sarkar F.H. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett 2013, 338:94-100.
75. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
76. Vesuna F., Lisok A., Kimble B., Raman V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009, 11:1318-1328.
77. Yang M.H., Hsu D.S., Wang H.W., Wang H.J., Lan H.Y., Yang W.H., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol 2010, 12:982-992.
78. Zhu H., Wang D., Zhang L., Xie X., Wu Y., Liu Y., et al. Upregulation of autophagy by hypoxia-inducible factor-1alpha promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia. Oncol. Rep 2014.
79. Zhou W., Lv R., Qi W., Wu D., Xu Y., Liu W., et al. Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. PLoS ONE 2014, 9:e87409.
80. Wang Z., Ali S., Banerjee S., Bao B., Li Y., Azmi A.S., et al. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J. Cell. Physiol 2013, 228:556-562.
81. Takao S., Ding Q., Matsubara S. Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. J. Hepatobiliary Pancreat Sci 2012, 19:614-620.
82. Hamada S., Masamune A., Shimosegawa T. Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front. Physiol 2013, 4:318.
83. Boyle S.T., Kochetkova M. Breast cancer stem cells and the immune system: promotion, evasion and therapy. J. Mammary Gland Biol. Neoplasia 2014, 19:203-211.
84. Chen S., Huang E.H. The colon cancer stem cell microenvironment holds keys to future cancer therapy. J. Gastrointest. Surg 2014, 18:1040-1048.
85. Rasheed Z.A., Yang J., Wang Q., Kowalski J., Freed I., Murter C., et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst 2010, 102:340-351.
86. Rasheed Z.A., Matsui W. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J. Gastroenterol. Hepatol 2012, 27(Suppl. 2):15-18.
87. Liang Z., Bian X., Shim H. Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast Cancer Res. Treat 2014, 146:535-542.
88. Shen B., Zheng M.Q., Lu J.W., Jiang Q., Wang T.H., Huang X.E. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. Asian Pac. J. Cancer Prev 2013, 14:5403-5408.
89. Zhang Y., Wei J., Wang H., Xue X., An Y., Tang D., et al. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Oncol. Rep 2012, 27:1599-1605.
90. Diaz-Lopez A., Moreno-Bueno G., Cano A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag. Res 2014, 6:205-216.
91. Kruger S., Haas M., Ormanns S., Bachmann S., Siveke J.T., Kirchner T., et al. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. World J. Gastroenterol 2014, 20:10769-10777.
92. Mittal A., Chitkara D., Behrman S.W., Mahato R.I. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 2014, 35:7077-7087.
93. Lee C.J., Dosch J., Simeone D.M. Pancreatic cancer stem cells. J. Clin. Oncol 2008, 26:2806-2812.
94. Richard V., Nair M.G., Santhosh Kumar T.R., Pillai M.R. Side population cells as prototype of chemoresistant, tumor-initiating cells. Biomed. Res. Int 2013, 2013:517237.
95. Cojoc M., Mabert K., Muders M.H., Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin. Cancer Biol 2014.
96. Hong S.P., Wen J., Bang S., Park S., Song S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009, 125:2323-2331.
97. Hermann P.C., Trabulo S.M., Sainz B., Balic A., Garcia E., Hahn S.A., et al. Multimodal treatment eliminates cancer stem cells and leads to long-term survival in primary human pancreatic cancer tissue xenografts. PLoS ONE 2013, 8:e66371.
98. Wang D., Zhu H., Zhu Y., Liu Y., Shen H., Yin R., et al. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. Acta Histochem 2013, 115:349-356.
99. Lonardo E., Hermann P.C., Heeschen C. Pancreatic cancer stem cells - update and future perspectives. Mol. Oncol 2010, 4:431-442.
100. Van den Broeck A., Gremeaux L., Topal B., Vankelecom H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 2012, 12:354.
101. Fitzgerald T.L., McCubrey J.A. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv. Biol. Regul 2014, 56:45-50.
102. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther 2008, 7:2725-2735.
103. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007, 67:2187-2196.
104. Moyret-Lalle C., Ruiz E., Puisieux A. Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer. World J. Clin. Oncol 2014, 5:311-322.
105. Karamitopoulou E. Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link?. Front. Oncol 2013, 3:221.
106. Ding X.M. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin. J. Cancer 2014, 33:140-147.
107. Balic A., Sorensen M.D., Trabulo S.M., Sainz B., Cioffi M., Vieira C.R., et al. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol. Cancer Ther 2014, 13:1758-1771.
108. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
109. Coco C., Zannoni G.F., Caredda E., Sioletic S., Boninsegna A., Migaldi M., et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J. Exp. Clin. Cancer Res 2012, 31:71.
110. Piscuoglio S., Lehmann F.S., Zlobec I., Tornillo L., Dietmaier W., Hartmann A., et al. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. J. Clin. Pathol 2012, 65:140-145.
111. Langan R.C., Mullinax J.E., Raiji M.T., Upham T., Summers T., Stojadinovic A., et al. Colorectal cancer biomarkers and the potential role of cancer stem cells. J. Cancer 2013, 4:241-250.
112. Ohara Y., Oda T., Sugano M., Hashimoto S., Enomoto T., Yamada K., et al. Histological and prognostic importance of CD44(+)/CD24(+)/EpCAM(+) expression in clinical pancreatic cancer. Cancer Sci 2013, 104:1127-1134.
113. Ding Q., Miyazaki Y., Tsukasa K., Matsubara S., Yoshimitsu M., Takao S. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Mol. Cancer 2014, 13:15.
114. Van den Broeck A., Vankelecom H., Van Delm W., Gremeaux L., Wouters J., Allemeersch J., et al. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. PLoS ONE 2013, 8:e73968.
115. Chen L., Fan J., Chen H., Meng Z., Chen Z., Wang P., et al. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci. Rep 2014, 4:5911.